Healthcare
Telo Genomics Corp.(TDSGF)
Live Price
Offline$0.039
+0.00% today
1Y Change
-16.48%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $10.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +40.0%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Telo Genomics Corp. (TDSGF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.04 and down 16.5% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +40.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +40.0%, free cash flow +5.4% with operating margin 0.0% and ROIC 663.9%. Stock Foundry combines TDSGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +40.0%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +17.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | +0.0% | โ | โ |
2026 Mar 2, 2026 | โ | +0.0% | +7.9% | -5.9% |
2025 May 26, 2025 | โ | +0.0% | +27.8% | +40.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TDSGF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TDSGF Max Drawdown
-63.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TDSGF and SPY.
Company Overview
Telo Genomics Corp.
Other OTC
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
- Leadership
- John Allen Farlinger
- IPO Date
- Jan 8, 2021
- Employees
- 8
- Street Address
- MaRS Centre
- Mailing
- Toronto, ON, M5G 1L7
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- 416-673-8487
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +40.0%
- Free Cash Flow
- +5.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -990.6%
- ROIC
- 663.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.14
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.